Replimune’s Shares Plunge After FDA Rejects Melanoma Drug Application

Replimune; RP1; FDA rejection; melanoma; cancer drug; Complete Response Letter; clinical trial design; objective response rate; share price drop

Oncology Market in 2025: Innovation, Growth, and Patient-Centric Care

Cancer immunotherapy, Targeted therapies , Precision medicine, AI in oncology, Combination treatments, Biosimilars, Clinical trial design, Personalized cancer care

Director/Vice President of Translational Research: Leading the Bridge from Discovery to Clinical Development

Translational Research, Biomarker Discovery, Preclinical Development, Early Clinical Development, Drug Molecule Development, Translational Science Leadership, Biomarker Development, Target Engagement Strategies, Assay Development (PK/ PD/ Immunogenicity), Clinical Trial Design, Endpoint and Biomarker Strategy, Team Building and Leadership, Cross-Functional Collaboration, Regulatory Approvals